Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial.
Krug D, Baumann R, Krockenberger K, Vonthein R, Schreiber A, Boicev A, Würschmidt F, Weinstrauch E, Eilf K, Andreas P, Höller U, Dinges S, Piefel K, Zimmer J, Dellas K, Dunst J. Krug D, et al. Among authors: dellas k. Strahlenther Onkol. 2021 Jan;197(1):48-55. doi: 10.1007/s00066-020-01689-7. Epub 2020 Oct 1. Strahlenther Onkol. 2021. PMID: 33001241 Free PMC article. Clinical Trial.
Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial.
Krug D, Vonthein R, Schreiber A, Boicev AD, Zimmer J, Laubach R, Weidner N, Dinges S, Hipp M, Schneider R, Weinstrauch E, Martin T, Hörner-Rieber J, Olbrich D, Illen A, Heßler N, König IR, Dellas K, Dunst J. Krug D, et al. Among authors: dellas k. Strahlenther Onkol. 2021 Sep;197(9):802-811. doi: 10.1007/s00066-020-01730-9. Epub 2020 Dec 15. Strahlenther Onkol. 2021. PMID: 33320286 Free PMC article. Clinical Trial.
Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials.
Pfaffendorf C, Vonthein R, Krockenberger-Ziegler K, Dellas K, Schreiber A, Uhlemann D, Dinges S, Würschmidt F, Andreas P, Weinstrauch E, Eilf K, Rades D, Höller U, Combs SE, Kazmierczak R, Fehlauer F, Schreck U, Zimmer J, Dunst J, Krug D. Pfaffendorf C, et al. Among authors: dellas k. Breast. 2022 Aug;64:136-142. doi: 10.1016/j.breast.2022.05.008. Epub 2022 Jun 2. Breast. 2022. PMID: 35691249 Free PMC article. Clinical Trial.
Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study.
Kuhnt T, Schreiber A, Pirnasch A, Hautmann MG, Hass P, Sieker FP, Engenhart-Cabillic R, Richter M, Dellas K, Dunst J. Kuhnt T, et al. Among authors: dellas k. Strahlenther Onkol. 2017 Sep;193(9):733-741. doi: 10.1007/s00066-017-1145-6. Epub 2017 May 12. Strahlenther Onkol. 2017. PMID: 28500491 Clinical Trial. English.
Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.
Jiang P, Krockenberger K, Vonthein R, Tereszczuk J, Schreiber A, Liebau S, Huttenlocher S, Imhoff D, Balermpas P, Keller C, Dellas K, Baumann R, Rödel C, Hildebrandt G, Jünemann KP, Merseburger AS, Katz A, Ziegler A, Blanck O, Dunst J. Jiang P, et al. Among authors: dellas k. Radiat Oncol. 2017 Aug 18;12(1):138. doi: 10.1186/s13014-017-0872-2. Radiat Oncol. 2017. PMID: 28821268 Free PMC article. Clinical Trial.
Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters.
Kappler M, Taubert H, Holzhausen HJ, Reddemann R, Rot S, Becker A, Kuhnt T, Dellas K, Dunst J, Vordermark D, Hänsgen G, Bache M. Kappler M, et al. Among authors: dellas k. Strahlenther Onkol. 2008 Aug;184(8):393-9. doi: 10.1007/s00066-008-1813-7. Strahlenther Onkol. 2008. PMID: 18956515
24 results